Despite the identification of recurrent potentially clinically targetable alterations including NOTCH1 mutations [7], KMT2A rearrangements (KMT2Ar) [8], and the NUP214::ABL1 gene fusion [9], T-ALL patients are routinely treated with intensive chemotherapy regardless of genotype [10]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.